RNA targeting with CRISPR–Cas13

RNA has important and diverse roles in biology, but molecular tools to manipulate and measure it are limited. For example, RNA interference1-3 can efficiently knockdown RNAs, but it is prone to off-target effects4, and visualizing RNAs typically relies on the introduction of exogenous tags5. Here we...

Full description

Bibliographic Details
Main Authors: Essletzbichler, Patrick, Belanto, Joseph J., Verdine, Vanessa, Kellner, Max J., Voytas, Daniel F., Gootenberg, Jonathan S, Han, Shuo, Joung, Julia, Cox, David Benjamin Turitz, Regev, Aviv, Lander, Eric Steven, Zhang, Feng, Abudayyeh, Omar O., Ting, Alice Y.
Other Authors: Harvard University--MIT Division of Health Sciences and Technology
Format: Article
Published: Nature Publishing Group 2018
Online Access:http://hdl.handle.net/1721.1/116680
https://orcid.org/0000-0002-7979-3220
https://orcid.org/0000-0001-6656-5002
https://orcid.org/0000-0001-7626-4254
https://orcid.org/0000-0001-8567-2049
https://orcid.org/0000-0002-8277-5226
https://orcid.org/0000-0003-2782-2509
Description
Summary:RNA has important and diverse roles in biology, but molecular tools to manipulate and measure it are limited. For example, RNA interference1-3 can efficiently knockdown RNAs, but it is prone to off-target effects4, and visualizing RNAs typically relies on the introduction of exogenous tags5. Here we demonstrate that the class 2 type VI6,7 RNA-guided RNA-targeting CRISPR-Cas effector Cas13a8(previously known as C2c2) can be engineered for mammalian cell RNA knockdown and binding. After initial screening of 15 orthologues, we identified Cas13a from Leptotrichia wadei (LwaCas13a) as the most effective in an interference assay in Escherichia coli. LwaCas13a can be heterologously expressed in mammalian and plant cells for targeted knockdown of either reporter or endogenous transcripts with comparable levels of knockdown as RNA interference and improved specificity. Catalytically inactive LwaCas13a maintains targeted RNA binding activity, which we leveraged for programmable tracking of transcripts in live cells. Our results establish CRISPR-Cas13a as a flexible platform for studying RNA in mammalian cells and therapeutic development.